354 Stock Overview
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.00 |
| 52 Week High | US$38.60 |
| 52 Week Low | US$22.00 |
| Beta | 0.76 |
| 1 Month Change | -14.18% |
| 3 Month Change | -29.88% |
| 1 Year Change | -31.14% |
| 3 Year Change | 31.43% |
| 5 Year Change | 29.21% |
| Change since IPO | 64.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 354 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.0% | 2.1% | 2.4% |
| 1Y | -31.1% | -23.4% | 2.0% |
Return vs Industry: 354 underperformed the German Pharmaceuticals industry which returned -23.4% over the past year.
Return vs Market: 354 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 354 volatility | |
|---|---|
| 354 Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 354 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 354's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 357 | Vikram Karnani | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| 354 fundamental statistics | |
|---|---|
| Market cap | €729.11m |
| Earnings (TTM) | €60.92m |
| Revenue (TTM) | €555.99m |
12.2x
P/E Ratio1.3x
P/S RatioIs 354 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 354 income statement (TTM) | |
|---|---|
| Revenue | US$631.45m |
| Cost of Revenue | US$83.53m |
| Gross Profit | US$547.92m |
| Other Expenses | US$478.73m |
| Earnings | US$69.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 86.77% |
| Net Profit Margin | 10.96% |
| Debt/Equity Ratio | 425.2% |
How did 354 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 03:49 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Collegium Pharmaceutical, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dana Flanders | Guggenheim Securities, LLC |
| Antonio Arce | H.C. Wainwright & Co. |
| Oren Livnat | H.C. Wainwright & Co. |